| Assessment Status | Rapid Review complete |
| HTA ID | - |
| Drug | Crizotinib |
| Brand | Xalkori® |
| Indication | For the first-line treatment of adults with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). |
| Assessment Process | |
| Rapid review commissioned | 06/02/2017 |
| Rapid review completed | 24/04/2017 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Not Recommended. |